


**Figure S1.** Schematic of the population pharmacokinetic model of aprepitant in pediatric patients. The structural model also included an allometric component accounting for body size on both central and peripheral clearance and volume, and effect of ontogeny (CYP3A4 maturation) on systemic clearance.



*CL*, systemic clearance; *F1*, bioavailability; *Ka*, first-order absorption constant; *Q*, intercompartmental clearance; *Tlag*, lag time (delay in absorption); *V2*, central volume of distribution; *V3*, peripheral volume of distribution.